MacroGenics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

CEO

Scott E. Koenig

CEOScott E. Koenig

Employees

341

Employees341

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2000

Founded2000

Employees

341

Employees341

MGNX Key Statistics

Market cap

99.68M

Market cap99.68M

Price-Earnings ratio

-1.78

Price-Earnings ratio-1.78

Dividend yield

—

Dividend yield—

Average volume

841.88K

Average volume841.88K

High today

$1.62

High today$1.62

Low today

$1.49

Low today$1.49

Open price

$1.49

Open price$1.49

Volume

1.05M

Volume1.05M

52 Week high

$5.10

52 Week high$5.10

52 Week low

$0.9897

52 Week low$0.9897

Analyst ratings

67%

of 6 ratings

Buy

33.3%

Hold

66.7%

Sell

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.